Investors comparing two clinical-stage biotechnology names often face the same question: which stock better balances scientific potential, financial staying power, and near-term catalysts? LRMR and VIR both operate in high-risk, high-reward segments of healthcare, yet they differ sharply in pipeline focus, scale, and recent price behavior. This stock comparison is most relevant to growth-oriented traders and investors evaluating relative performance and market positioning between a focused rare-disease developer and a diversified infectious-disease and oncology platform. The analysis below reviews each company's recent performance, growth drivers, and risk profile to provide a balanced, data-driven perspective.
LRMR, or Larimar Therapeutics, is a clinical-stage biotechnology company developing nomlabofusp, its lead product candidate for Friedreich's ataxia, a rare, progressive, and fatal neuromuscular disease. In recent weeks, the company has continued advancing its regulatory program, having previously submitted the first module of a rolling BLA (Biologics License Application) and reported positive open-label data showing sustained increases in frataxin protein levels. The company also recently strengthened its executive team with the appointment of a president and chief operating officer.
From a market standpoint, LRMR has traded with notable volatility. Although the stock has posted a positive return over the trailing year, it has pulled back meaningfully in recent market activity, reflecting the binary, catalyst-dependent nature of a small-cap, pre-revenue biotech. Analysts maintain a broadly constructive view, with a consensus "Strong Buy" rating and an average price target well above recent trading levels, but the shares carry a relatively modest market capitalization and a cash runway extending into 2027. Sentiment remains tied closely to regulatory milestones and clinical data readouts.
VIR, or Vir Biotechnology, is a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Its pipeline includes a hepatitis delta program built around elebsiran and tobevibart, as well as several PRO-XTEN masked T-cell engagers targeting HER2, PSMA, and EGFR in solid tumors. In recent weeks, the company reported third-quarter results that showed a narrower net loss, announced a research collaboration with Gilead, and received FDA Fast Track designation for VIR-5500 in late-line metastatic castration-resistant prostate cancer.
Market performance has been a standout for VIR, with the stock roughly doubling over the past year and outpacing the broader market by a wide margin. The company's larger cash position—reinforced by recent partnership proceeds—and a stated runway into the second half of 2028 provide a stronger financial cushion than many peers. Sentiment has been supported by multiple near-term catalysts, including a key Phase 3 data readout for the hepatitis delta program. Analysts generally rate the stock a "Buy," with an average target above the current share price.
Tickeron's Trending AI Robots page highlights a curated selection of the platform's AI trading bots, chosen for their suitability to current market conditions. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of symbols. Because no single approach fits every market environment, only a subset of these bots earns a place in the Trending section at any given time. The page lets investors compare bots side by side and observe which automated strategies are currently gaining traction. For traders evaluating names like LRMR and VIR, exploring these Trending AI Robots can offer an additional, data-driven perspective on market positioning.
The two companies diverge in several important dimensions. LRMR is a concentrated, single-asset rare-disease story: its valuation hinges primarily on the regulatory and commercial success of one candidate, nomlabofusp. This focus can magnify both upside and downside around clinical and regulatory milestones. VIR, by contrast, operates a broader portfolio spanning hepatitis delta and multiple oncology programs, with partnerships that provide external validation and milestone-based funding.
On momentum, VIR has demonstrated greater recent strength, while LRMR has experienced a pullback in recent weeks despite solid longer-term returns. Financially, VIR holds a substantially larger cash balance and longer runway, reducing near-term financing risk relative to LRMR. Sector exposure also differs: LRMR is tied to rare neuromuscular disease, while VIR spans infectious disease and immuno-oncology. Both remain pre-revenue and loss-making, so risk is elevated across both names, but the breadth of catalysts and financial flexibility currently differ considerably.
Based on observable factors including trend consistency, catalyst breadth, balance-sheet stability, and relative market positioning, Tickeron's AI would currently lean toward VIR over LRMR. The AI's assessment reflects VIR's stronger recent momentum, a more diversified pipeline, a larger cash reserve, and a broader slate of near-term catalysts. While LRMR retains meaningful potential tied to its focused regulatory path, its more binary, single-asset profile introduces greater variability in outcomes. This view is expressed in probabilistic terms and may shift as new data and market conditions emerge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LRMR's Aroon Indicator triggered a bullish signal on November 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 152 similar instances where the Aroon Indicator showed a similar pattern. In 129 of the 152 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LRMR's RSI Indicator exited the oversold zone, 24 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LRMR as a result. In 79 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for LRMR just turned positive on October 21, 2026. Looking at past instances where LRMR's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
LRMR moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where LRMR advanced for three days, in 214 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LRMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
LRMR broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LRMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.949) is normal, around the industry mean (3.596). P/E Ratio (-1.189) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LRMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In 37 of the 41 cases the stock fell afterwards. This puts the odds of success at 90%.
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 70 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
VIR moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.596). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (443.347).
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LRMR | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 39 | 47 | |
P/E GROWTH RATING 1..100 | 13 | 82 | |
SEASONALITY SCORE 1..100 | 42 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (19) in the null industry is somewhat better than the same rating for LRMR (58). This means that VIR’s stock grew somewhat faster than LRMR’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as LRMR (100). This means that VIR’s stock grew similarly to LRMR’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as LRMR (100). This means that VIR’s stock grew similarly to LRMR’s over the last 12 months.
LRMR's Price Growth Rating (39) in the null industry is in the same range as VIR (47). This means that LRMR’s stock grew similarly to VIR’s over the last 12 months.
LRMR's P/E Growth Rating (13) in the null industry is significantly better than the same rating for VIR (82). This means that LRMR’s stock grew significantly faster than VIR’s over the last 12 months.
| LRMR | VIR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 73% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 78% |
| Advances ODDS (%) | 10 days ago 84% | 12 days ago 76% |
| Declines ODDS (%) | 4 days ago 88% | 1 day ago 81% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | N/A |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LRMR’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LRMR’s TA Score shows that 6 TA indicator(s) are bullish while VIR’s TA Score has 3 bullish TA indicator(s).
LRMR (@Biotechnology) experienced а +19.26% price change this week, while VIR (@Biotechnology) price change was -26.82% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -9.27%. For the same industry, the average monthly price growth was -14.83%, and the average quarterly price growth was -25.31%.
LRMR is expected to report earnings on Mar 19, 2027.
VIR is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with AMLX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To LRMR | 1D Price Change % | ||
|---|---|---|---|---|
| LRMR | 100% | -0.16% | ||
| AMLX - LRMR | 45% Loosely correlated | -1.58% | ||
| CLDX - LRMR | 44% Loosely correlated | +1.49% | ||
| VIR - LRMR | 44% Loosely correlated | -3.06% | ||
| MLTX - LRMR | 42% Loosely correlated | +2.22% | ||
| VYGR - LRMR | 41% Loosely correlated | -3.59% | ||
More | ||||
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -3.06% | ||
| BEAM - VIR | 55% Loosely correlated | -0.33% | ||
| CADL - VIR | 53% Loosely correlated | -3.57% | ||
| BCYC - VIR | 53% Loosely correlated | -1.93% | ||
| EDIT - VIR | 52% Loosely correlated | -3.39% | ||
| SLDB - VIR | 51% Loosely correlated | +1.42% | ||
More | ||||